UTMB-Novartis Alliance for Pandemic Preparedness

UTMB-诺华流行病防范联盟

• 批准号: 10514146
• 负责人: Thierry Diagana
• 金额: $ 5616.36万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-16 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10514146
• 关键词: 2019-nCoV; Academia; Air; Antiviral Agents; Biology; COVID-19; COVID-19 assay; COVID-19 pandemic; Cells; Cessation of life; Clinical; Collaborations; Communicable Diseases; Communication; Complex; Coronavirus; Data; Decision Making; Dengue; Development; Diagnostic; Drug Targeting; Education; Emerging Technologies; Ensure; Faculty; Family; Flavivirus; Foundations; Future; Generations; Goals; Government; Hendra Virus; Henipavirus; Home; Human; Industry; Infection; Institution; Intellectual Property; Investments; Laboratories; Learning; Libraries; Life; Machine Learning; Medical; Medicine; Membrane Proteins; Mentors; Middle East Respiratory Syndrome Coronavirus; Nipah Virus; Nongovernmental Organizations; Nucleosides; Nucleotides; Oral; Peptide Hydrolases; Pharmaceutical Preparations; Pharmacologic Substance; Phase I Clinical Trials; Phenotype; Polymerase; Population Density; Postdoctoral Fellow; Predisposition; Prevention; Private Sector; Privatization; Probability; Process; Productivity; Quantitative Structure-Activity Relationship; RNA-Directed RNA Polymerase; Readiness; Research; Research Activity; Research Project Grants; Resistance; SARS-CoV-2 inhibitor; Seasons; Serotyping; Technology; Texas; Training; Translational Research; Travel; United States National Institutes of Health; Universities; Vaccines; Viral; Virus; base; biosafety level 4 facility; clinical candidate; clinical investigation; combat; drug candidate; drug discovery; economic cost; influenzavirus; inhibitor; innovation; mortality; multidisciplinary; new technology; next generation; novel; pandemic disease; pandemic preparedness; programs; public health relevance; public-private partnership; recruit; response; role model; screening; student training; success; synergism; translational impact; virology

OVERALL – ABSTRACT Pandemic prevention and preparedness is a major scientific and societal priority that requires sustained and forward looking investments across governmental, non-governmental, academic and private sectors to develop an arsenal of countermeasures against the existential threat of viral pandemics. Combining world-leading BSL3/4 capabilities at University of Texas of Medical Branch (UTMB) and state-of-the art drug discovery technologies at Novartis, the UTMB Novartis Alliance for Pandemic Preparedness (UNAPP), is a unique and innovative partnership that brings together the multi-disciplinary expertise required to deliver high quality antiviral drug candidates. Enabled by world-leading virologists and seasoned drug hunters, UNAPP will aggressively prosecute a portfolio of 5 projects aiming to discover orally available, safe, and effective drugs against coronaviruses, flavivirus and henipavirus, three major classes of viruses with pandemic potential. The projects portfolio combines approaches targeting well validated drug targets, such as the RNA- dependent RNA polymerases and viral proteases, as well as phenotypic screening, which will allow for the discovery of clinical drug candidates and novel targets that will advance our fundamental understanding of the biology of those viruses. Four scientific Cores—Virology, High-Throughput Biology, Drug Discovery and Translational Research Cores—will provide technological and scientific expertise to support Project Teams and implement the scientific strategy toward novel antiviral drugs. The UNAPP will be governed by an Administrative Core which will be co-led by the PIs, Dr. Pei-Yong Shi and Dr. Thierry Diagana, who have a long track-record of successfully working together. Both PIs have led multiple productive collaborations focused on translational impact and combining public, private and non-governmental organizations. The Administrative Core will provide integrated decision making in scientific, operational, financial, intellectual property protection, and communication. In collaboration with all project and Core leaders, as well as with external input from a Scientific Advisory Board and NIH program officers, they will ensure that the projects portfolio leverages the full spectrum of technologies and capabilities residing in all four scientific Cores, capturing synergies across projects through cross-learning and efficient deployment of platforms relevant to multiple viruses. Because of the unique complementarity of the scientific Cores and the remarkable synergies of the project portfolio, we fully expect that the UNAPP will yield exceptional productivity and deliver all the proposed objectives: (1) Deliver 3 IND-ready candidates and 3 Development Candidates, (2) advance antiviral research, and (3) train next-generation drug hunters.

总体 – 摘要 大流行病的预防和准备是一项重大的科学和社会优先事项，需要持续和 政府、非政府、学术和私营部门的前瞻性投资，以发展 针对病毒性流行病的生存威胁的一系列对策。结合世界领先 德克萨斯大学医学分校 (UTMB) 的 BSL3/4 能力和最先进的药物发现 诺华 (UTMB) 诺华流行病防范联盟 (UNAPP) 的技术是一个独特的 和创新的合作伙伴关系，汇集了提供高质量所需的多学科专业知识 抗病毒候选药物。在世界领先的病毒学家和经验丰富的药物猎人的支持下，UNAPP 将 积极推进 5 个项目组合，旨在发现口服、安全和有效的药物 对抗冠状病毒、黄病毒和亨尼帕病毒这三大类大流行病毒 潜在的。该项目组合结合了针对经过充分验证的药物靶点的方法，例如 RNA- 依赖的RNA聚合酶和病毒蛋白酶，以及表型筛选，这将允许 临床候选药物和新靶点的发现将增进我们对药物的基本理解 这些病毒的生物学。四大科学核心——病毒学、高通量生物学、药物发现和 转化研究核心——将提供技术和科学专业知识来支持项目团队和 实施新型抗病毒药物的科学战略。 UNAPP 将由行政部门管理 核心将由 PI 博士 Pei-Yong Shi 和 Thierry Diagana 博士共同领导，他们在 成功合作。两位 PI 都领导了多次富有成效的合作，重点关注转化 影响和结合公共、私人和非政府组织。行政核心将提供 科学、运营、财务、知识产权保护等方面的综合决策 沟通。与所有项目和核心领导者合作，以及科学界的外部投入 顾问委员会和 NIH 项目官员，他们将确保项目组合利用全方位 驻留在所有四个科学核心的技术和能力，通过以下方式捕获跨项目的协同效应 多种病毒相关平台的交叉学习和高效部署。因为独特 科学核心的互补性和项目组合的显着协同效应，我们完全期望 UNAPP 将产生卓越的生产力并实现所有拟议目标：(1) 实现 3 IND 就绪 候选人和 3 名发展候选人，(2) 推进抗病毒研究，以及 (3) 培训下一代 毒品猎人。